Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Hematopoietic Stem Cell Transplantation (HSCT): Final Data from an Expanded-Access Protocol

VOD/SOS is an unpredictable, potentially life-threatening complication of conditioning regimens for HSCT; VOD/SOS with multi-organ dysfunction (MOD) may be associated with>80% mortality. Defibrotide is approved to treat hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the US and to treat severe hepatic VOD/SOS post-HSCT in the EU.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research